Comments for IMCL - Stockpickr! Your Source for Stock Ideas

Comments for IMCL

Added By	Comments	Type	Date Added
barrons2	News of the Bristol-Meyers (BMY) offer to buy out ImClone (IMCL) deal triggered a flurry of option activity in Amgen (AMGN), Onyx Pharmaceuticals (ONXX), and Amylin (AMLN) said option strategist Frederic Ruffy.	Love	August 06, 2008
barrons2	As of March 31st the following were Carl Icahn’s top 5 holdings; Biogen (BIIB), Blockbuster (BBI), Imclone (IMCL), Motorola (MOT) and Yahoo! (YHOO). This hasn’t been the best Carl year, observes Karen Finerman. Sometimes the most talented doctors have patients who die, adds Jeff Macke.	Love	July 30, 2008
barrons2	We’re talking about lung cancer, explains CNBC Pharmaceuticals Reporter Mike Huckman. Look for headline-grabbing test results out of ImClone (IMCL).	Love	May 29, 2008
TMG	Favorite bio-tech.	Love	September 30, 2007
sarah z	Finally, we have ImClone Systems making the list. This biotech's CEO, John H. Johnson, recently purchased 13,609 shares worth half a million dollars. Just days later, the stock rocketed 18% following positive news about ImClone's cancer drug Erbitux. Johnson says it was just "pure confidence." After Johnson took the job at ImClone on Aug. 27, he agreed to buy $500,000 worth of company stock within 90 days of joining the company. Johnson bought 13,609 shares for an average price of $36.74, and within 3 days he saw the stock surge 6.97 per share- not a bad return on his investment. "The company believes it is important for a CEO to use his own money to buy stock of ImClone -- so he's not just working with stock option money but using his own funds," ImClone's general counsel Daniel O'Connor said. "That leaves him standing in the same shoes as his shareholders." The great timing of Johnson's purchase touches a sensitive subject at ImClone. In late 2001, original ImClone CEO, Sam Waksal, and buddy Martha Stewart, were thrown in jail for making trades based on insider information about Erbitux. Another positive note for ImClone is that analysts at Rodman & Renshaw reiterated a market outperform rating on the company. They believe positive trial results for its drug Erbitux will prove that it is effective against lung cancer. They also mention that shares plunged 11% last Friday following an unjustified downgrade by another equity research firm. The firm stated predictions about the trial results which Rodman & Renshaw believe to be too low and statistically insignificant. Rodman’s statistical assumptions, calculated by Dr. Elaine Allen, Associate Professor of Statistics & Entrepreneurship at Babson College, show phase 3 studies of Erbitux report an increase in overall survival. Dr. Allen has predicted the outcomes of drugs including the rejection of Gilead’s adefovir for HIV and OSI Pharmaceutical’s BR.21 trial of Tarceva for advanced NSCLC. Another note, Genetech's Avastin will continue to be the leader in lung cancer treatment, but Erbitux will significantly expand into the market for patients who are ineligible for Avastin. Rodman & Renshaw raise their target price to $55 based on ImClone's positive trial results, 3-year EPS of 22%, and forward P/E of 23.	Love	September 19, 2007
Phantom	diversifying into biotech	Love	September 11, 2007
dennis schultz	selling low	Love	August 22, 2007
TWK	Chart	Love	May 28, 2007
stockerblog	6.3 million short	Love	May 26, 2007
spriggster	Following Carl Icahn on this one. So far so good.	Love	April 14, 2007
rajwani	this company has good cancer drug in place without competition	Love	March 29, 2007
Mayukh	imclone systems incorporated	Love	March 17, 2007
warrenyost	suspected lack of ethics	Hate	January 18, 2007
One Tree Hill LP	Icahn is nervous	Hate	December 08, 2006